BioSenic progresses cGvHD system and submits patent to EPO
Patent will allow the development of an industrial biomarker analysis kit which could be available worldwide
Read More
Tag: cGVHD
AbbVie/Janssen’s Imbruvica filed for graft-versus-host-disease
US regulators have agreed to review AbbVie and Janssen’s Imbruvica for previously treated chronic graft-versus-host-disease (cGVHD), a severe, potentially life-threatening consequence of stem cell or bone marrow transplant.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
